Strategic Cooperation | Haibu Pharmaceutical and Kelin Likang have reached a strategic cooperation.

On November 12, 2021, the signing ceremony of the strategic cooperation agreement between Beijing Haibu Pharmaceutical Technology Co., Ltd. and Beijing Kelin Likang Medical Research Co., Ltd. was held at Haibu Pharmaceutical. Mr. Xu Yu, founder and CEO of Kelin Likang, Mr. Zhou Jianguo, Senior Vice President of Public Affairs, and representatives from the Business Development Department attended the signing ceremony with the Haibu Pharmaceutical representative team.

Photo: Group photo of representatives from both parties at the strategic cooperation signing ceremony.

Ms. Liu Changru, Chairman and General Manager of Haibu Pharmaceutical, and Mr. Xu Yu, founder and CEO of Kelin Likang, delivered speeches at the signing ceremony, elaborating on their respective companies' business characteristics and advantages, and expressing expectations for future cooperation between both parties. Based on Haibu Pharmaceutical's technical strength and advantages in chemical drug research and development, Kelin Likang has rich research resources and experience in clinical trials.Customer demand-oriented, based on mutual trust"With this concept in mind, we will work together sincerely to provide more professional and comprehensive services for upstream and downstream enterprises, institutions, and partners in the industry, promote faster market access for new drugs and good drugs, benefit patients, and create value.

Mr. Zhou Jianguo, Vice President of Public Affairs at Kelin Likang participated in the signing ceremony and delivered a speech introducing Kelin Likang's rapid development process in recent years as well as its full-process service capabilities for clinical trials.

In the future, both parties will carry out multi-faceted close cooperation in areas such as innovative drug pharmaceutical research, bioequivalence testing for generic drugs, confirmatory clinical trials, marketing authorization holder (MAH), pharmacovigilance, custom development of placebo or control drugs to achieve collaborative innovation and support industry development.

About Beijing Kelin Likang Medical Research Co., Ltd.

Beijing Kelin Likang Medical Research Co., Ltd. is a comprehensive medical technology service provider dedicated to clinical operations, drug regulatory registration, medical writing, biostatistics and data management, pharmacovigilance, call center services, quality assurance training and consulting services.

Kelin Likang is headquartered in Beijing with physical offices in Shanghai, Guangzhou,Tianjin ,Chengdu ,Xi'an ,Shenyang ,Suzhou ,Nanjing ,and Taipei among other locations; it also has resident monitors in over 20 cities. It has overseas offices in places like the United States ,the United Kingdom ,Canada ,and Singapore . Currently it has an international professional team of nearly 800 people.

Since its establishment in 2009,Kelin Likang has actively participated in clinical research and academic promotion in domestic and international medical fields providing specialized clinical services to pharmaceutical companies authoritative academic institutions clinical trial research institutions experts doctors etc helping patients achieve better health while rapidly growing into one of China's major contract research organizations for clinical trials with high-quality service reasonable prices a highly qualified team a complete quality management system high-quality efficient service rich experience in clinical research resulting in a repurchase rate as high as 85%.

About Beijing Haibu Pharmaceutical Technology Co., Ltd.

Beijing Haibu Pharmaceutical Technology Co., Ltd. has rich successful experience in the R&D of small molecule chemical drugs. In recent years，Haibu Pharmaceutical has actively explored compound design structural modification synthesis process optimization formulation technology improvement crystal form challenges etc related to small molecule chemical innovative drugs achieving some results.The Haibu team is well-versed with laws regulations technical guidelines related to small molecule chemical drug R&D possessing full-process efficient project management capabilities from project evaluation patent strategy design preclinical research clinical trial management drug registration to obtaining market access qualifications.